Baidu
map
CLIN EXP MED 润色咨询

CLINICAL AND EXPERIMENTAL MEDICINE

出版年份:2001 年文章数:527 投稿命中率: 开通期刊会员,数据随心看

出版周期:Quarterly 自引率:2.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2024-08-26 ms9000001272921253 来自福建省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向:细胞治疗;肿瘤免疫
    经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2024-04-13 国统乃我辈之愿 来自海南省

    去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-12-24 ms2000001657204792 来自上海

    一个月了,还在邀请审稿人,要是还邀请不到真开始慌了

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2024-04-05 罗磊 来自湖北省

    审稿速度:1.0
    经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-12-21 39314679eccv 来自湖北省

    这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-11-07 1226054bm42暂无昵称 来自广东省

    审稿速度:6.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;Meta分析
    经验分享:投稿的一篇Meta分析
    6月1号投稿
    6月3号送审
    10月30号返修
    11月1号修回
    11月7号接收
    外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-10-16 仅叹 来自重庆

    投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。
    ——————No.1——————
    2022.9.30 submission received
    2022.9.30 reviewers invited (21)
    2022.12.28 reviewers invited (22)
    2023.1.10 无审稿人接受审稿邀请→rejected
    ——————No.2——————
    2023.5.17 submission received
    2023.5.18 reviewers invited (27)
    2023.5.25 one reviewer accepted to review
    2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-07-04 国统乃我辈之愿 来自海南省

    偏重的研究方向:临床实验研究
    经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-07-05 采药者 来自广东省

    审稿速度:4.0
    偏重的研究方向:临床实验研究
    经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:细胞治疗;肿瘤免疫<br>经验分享:2024.7.15转投,2024.7.30审稿意见,小修,3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa,不要版面费,昨天投了一篇,怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了,还在邀请审稿人,要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0<br>经验分享:写的小分子RNA关于肿瘤的综述,投稿十天就返修了,希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了?因为要全面开放剔除非OA?还是本来就这么慢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;Meta分析<br>经验分享:投稿的一篇Meta分析<br>6月1号投稿<br>6月3号送审<br>10月30号返修<br>11月1号修回<br>11月7号接收<br>外审期间多次联系编辑,编辑都很耐心回复,总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇,均因无审稿意见而在投稿3+月后拒稿,浪费时间!建议慎投。<br>——————No.1——————<br>2022.9.30 submission received<br>2022.9.30 reviewers invited (21)<br>2022.12.28 reviewers invited (22)<br>2023.1.10 无审稿人接受审稿邀请→rejected<br>——————No.2——————<br>2023.5.17 submission received<br>2023.5.18 reviewers invited (27)<br>2023.5.25 one reviewer accepted to review<br>2023.8.27 只找到一个审稿人,并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向:临床实验研究<br>经验分享:4.10号投稿,5.13邀请审稿人,5.21审稿意见收到,6.5号修回,6.14接受,6.24号pubmed检索,预计7.10号wos可检索!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0<br>偏重的研究方向:临床实验研究<br>经验分享:投稿六个多月了,一审已经半年了还没有回信,中间催了一次,客套回复了一下,后来又问了一次,才知道找了24个审稿人,只有一个接受,然后半年没给出意见,半年了也没找新的审稿人,也不去催那个审稿人,无语了!唯一的希望就是告诉我已经电话联系了一个审稿人!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0<br>经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]
    2023-07-25 ms9000001799259170 来自云南省

    审稿速度:6.0
    经验分享:谨慎投稿!投稿三个多月毫无动静,最后发邮件给了拒稿,说找不到审稿人 真想骂人

    0

共177条页码: 1/18页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map